CDKAL1 rs4886407: Insulin Response and Metabolic Traits
The genetic variant rs4886407 is an intronic single nucleotide polymorphism located in the CDKAL1 gene on chromosome 6. Research links this variant to subtle differences in pancreatic beta-cell function, specifically quantitative variation in fasting insulin levels and insulin secretion dynamics. However, current clinical evidence remains limited, and the variant confers modest statistical associations rather than direct diagnostic power.
What each genotype means
Typical insulin secretion profile
This genotype is associated with baseline levels of fasting insulin and insulin secretion in population studies. Research suggests that variants in the CDKAL1 gene may influence how the body regulates insulin, but this specific genotype represents the common baseline observed in most individuals.
This is a common genotype found across most global populations, though exact frequencies vary by ancestry.
Intermediate insulin trait association
Individuals with this genotype carry one copy of the variant allele associated with minor shifts in fasting insulin and insulin secretion traits. These associations are based on statistical trends in large population studies and do not indicate a clinical diagnosis or specific health outcome.
This heterozygous genotype is frequently observed, appearing in a significant portion of the population across European, African, and East Asian ancestries.
Associated with insulin trait variation
This genotype is linked to quantitative variations in fasting insulin levels and insulin secretion markers in some genome-wide association studies. Because the evidence for this specific variant is limited, these findings reflect statistical correlations rather than direct clinical predictions; please discuss any metabolic concerns with your healthcare provider.
This genotype is present in a substantial subset of the population, with a minor allele frequency typically ranging between 0.20 and 0.35 in major ancestral groups.
Genetic Location and Variant Anatomy
The single nucleotide polymorphism rs4886407 is situated within an intronic sequence of the CDK5 regulatory subunit associated protein 1 like 1 (CDKAL1) gene on chromosome 6p22.3. Because it resides in a non-coding intron rather than a protein-coding exon, rs4886407 does not alter the primary amino acid sequence of the resulting CDKAL1 protein. Instead, variants in this genomic region are thought to serve as regulatory markers or tagging SNPs. Non-coding variants can influence transcriptional regulatory motifs, alter splicing efficiency, or sit in high linkage disequilibrium with other functional variations in the surrounding chromatin architecture, ultimately affecting how much functional protein is expressed in metabolic tissues.
Biological Role of the CDKAL1 Gene
The CDKAL1 gene encodes an enzyme that acts as a tRNA methylthiotransferase, specifically modifying tRNA(Lys) to ensure accurate and efficient translation of proinsulin in pancreatic islet beta-cells. Proper post-transcriptional tRNA modification prevents ribosomal stalling and misfolding during rapid insulin synthesis. Loss or impairment of CDKAL1 function compromises the cell's ability to maintain high-capacity insulin secretion during glucose challenges. Additionally, CDKAL1 has been implicated in blunting excessive CDK5 kinase activation, a process linked to beta-cell stress and glucotoxicity. Consequently, genomic variation throughout the CDKAL1 locus frequently connects to subtle alterations in beta-cell performance and systemic glycemic maintenance.
Clinical Research and Strength of Evidence
While several prominent landmark genome-wide association studies (GWAS) have established the CDKAL1 locus as an important contributor to type 2 diabetes and glycemic variation, direct evidence for rs4886407 itself is classified as limited. Published population studies identify rs4886407 as an intronic marker correlating with quantitative differences in fasting insulin concentrations and beta-cell response metrics. However, its estimated effect sizes are small, explaining only a modest fraction of metabolic variance. Furthermore, because linkage disequilibrium patterns differ between ancestral backgrounds, associations seen in one cohort may not translate identically across global populations, meaning rs4886407 acts as a minor statistical trait marker rather than a causal driver.
Navigating Personal Genetic Results
Understanding an rs4886407 genotype provides insight into underlying polygenic metabolic architecture, but it cannot diagnose insulin resistance, prediabetes, or type 2 diabetes. Common variants of modest effect operate in concert with hundreds of other genetic loci alongside pivotal lifestyle determinants, such as physical activity, nutrition, sleep quality, and body composition. Individuals carrying alleles statistically linked to lower insulin secretion should not interpret their results as a clinical certainty of disease. Routine standard-of-care laboratory evaluations, such as hemoglobin A1c and fasting blood glucose tests, remain the primary tools for assessing metabolic status, and any questions about personal health risks should be evaluated with a qualified healthcare professional.
How common is this variant?
The minor allele frequency (MAF) for rs4886407 typically ranges between approximately 0.20 and 0.35 across major global populations, including individuals of European, East Asian, and African ancestry.
Frequently asked questions
Does having the rs4886407 variant mean I will develop diabetes?
No. The rs4886407 variant is a common genetic marker with limited individual effect, associated only with subtle shifts in fasting insulin traits. It does not cause or diagnose diabetes on its own, and healthy lifestyle habits play a far more dominant role in metabolic health.
What does the CDKAL1 gene do in the body?
CDKAL1 produces an enzyme that modifies transfer RNA molecules to ensure accurate and smooth translation of proinsulin in pancreatic beta-cells. It helps preserve healthy pancreatic function and adequate insulin secretion when the body processes glucose.
Can diet or exercise change the effect of rs4886407?
While lifestyle changes cannot change your underlying DNA sequence, consistent physical activity and balanced nutrition directly support insulin sensitivity and beta-cell workload. Lifestyle factors generally have a far greater impact on long-term metabolic outcomes than individual minor genetic variants.
Should I order specialized testing if I carry rs4886407?
Specialized clinical testing is not indicated solely based on this variant. Standard preventive health checkups, including routine fasting glucose or hemoglobin A1c measurements performed by your healthcare provider, are the standard methods used to monitor metabolic wellness.
Sources & further reading
Educational information only, last refreshed 9/6/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs4886407?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CDKAL1
Associated with impaired insulin secretion and increased risk of type 2 diabetes; recent evidence suggests sex-specific effects on glycemic control.
This SNP in the CDKAL1 gene is linked to impaired insulin secretion and increased susceptibility to type 2 diabetes.
This SNP is a well-known marker associated with type 2 diabetes risk and impaired insulin secretion.